Clinical trials: Pulmonary Vascular Disease
Hypertension, Pulmonary
Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
An open label, long term extension to Study AMB112529. All subjects may remain in the extension study for a minimum of six months.
- Trial name
- NCT01342952
- Testing
- Ambrisentan
- Where
- 22 sites in United States, Argentina and 7 more
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis.
- Trial name
- NCT01613599
- Testing
- Rituximab
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Pulmonary Hypertension
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years.
- Trial name
- OPTION (NCT01389271)
- Testing
- Ventavis inhaled (Iloprost, BAYQ6256)
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Bayer
Pulmonary Hypertension
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
- Trial name
- NCT00467896
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Actelion
Submassive Pulmonary Embolism
ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with…
- Trial name
- ULTIMA (NCT01166997)
- Testing
- EkoSonic Endovascular System, Unfractionated heparin
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 59 people
- Sponsor
- Boston Scientific Corporation
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Stent-Retriever for Acute Massive Pulmonary Embolism (SRAME)
To evaluate treatment outcomes of patients diagnosed with pulmonary embolism.
- Trial name
- SRAME (NCT05992168)
- Testing
- Stent-Retriever
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Pulmonary Hypertension
Study of Ambrisentan in Participants With Pulmonary Hypertension
The primary objective of this study is to monitor the long-term safety of ambrisentan in adult participants with pulmonary hypertension.
- Trial name
- ABS-LT (NCT00777920)
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Argentina and 7 more
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Atherosclerosis
A Study To Determine The Effect Of SB-480848 On Asthma
The purpose of this study is to compare the effects of SB-480848 with placebo in subjects with asthma.
- Trial name
- NCT00368576
- Testing
- SB 480848, tablets
- Where
- 7 sites in United States, Germany
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week…
- Trial name
- NCT05612035
- Testing
- Frespaciguat
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Pulmonary Hypertension
Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension
This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.
- Trial name
- NCT05001711
- Testing
- Aria CV Acute PH System
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Aria CV, Inc
Wegeners Granulomatosis
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive…
- Trial name
- SPARROW (NCT01446211)
- Testing
- Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- Nordic Pharma SAS
Heart Defects, Congenital, Hypertension, Pulmonary
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery
This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery.
- Trial name
- NCT00335244
- Testing
- L-citrulline
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA)
Special Drug Use-results Survey for Long-term Use（Avacopan）
The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.
- Trial name
- NCT06758271
- Testing
- Avacopan
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]).
- Trial name
- AFFILIATE (NCT02060487)
- Testing
- sildenafil citrate
- Where
- 82 sites in United States, Australia and 21 more
- Volunteers
- 385 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Hypertension
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH.
- Trial name
- NCT00325403
- Testing
- Oral treprostinil (UT-15C) Sustained Release Tablets
- Where
- 77 sites in United States, Austria and 11 more
- Volunteers
- 349 people
- Sponsor
- United Therapeutics